Abstract
Background: bacterial-associated chronic cervicitis (CC) occupies a leading place in the cervical pathology structure. At the same time, the disease recurrence rate reaches 59–68% in the setting of resistance to antibacterial therapy, which determines the need to find new effective drugs. Aim: to evaluate the clinical efficacy, safety and compliance of therapy with minocycline in patients with bacterial-associated CC. Patients and Methods: a multicenter prospective observational clinical study was conducted in women's health clinics and medical centers in Yekaterinburg. The study included 60 female patients with a confirmed diagnosis of bacterial-associated CC. Group 1 (n=31) received the antibacterial drug minocycline (Minolexin®) 100 mg twice a day in the morning and evening, 10 days + antimycotic prebiotic 1 suppository once a day intravaginally for 6 days, starting from the 3rd day of antibiotic therapy. Group 2 (n=29) received doxycycline 100 mg twice a day for 10 days + antimycotic prebiotic 1 suppository once a day intravaginally for 6 days, starting from the 3rd day of antibiotic therapy. Clinical and laboratory efficacy (cervicitis signs, results of laboratory microbiome research methods) and drug tolerability were evaluated 10 and 30 days after the treatment initiation. Results: as a result of CC antibacterial therapy with minocycline, pathogen eradication was observed in 83.9% of female patients (group 2 — in 69.9%, p=0.0001), the original squamous epithelium 30 days after the minocycline was detected in 27 (87.1%) female patients (group 2 — in 19 (65.5±5.8%) female patients, p=0.0001), which indicates a higher efficacy of minocycline versus doxycycline. Patients of the minocycline group had more therapy adherence — 96.8% vs. 82.9% in the doxycycline group (p=0.0001) due to the minimal number of side effects (3.2% vs. 17.2%, respectively; p=0.0001). Conclusion: minocycline is a systemic antibiotic of the tetracycline group, which can be considered as the front-line drug for antibacterial therapy of patients with CC due to its high clinical efficacy, minimal risk of side effects and high compliance. KEYWORDS: chronic cervicitis, antibacterial therapy, tetracyclines, minocycline, efficacy. FOR CITATION: Dobrokhotova Yu.E., Kononova I.N., Kareva E.N., Shmakova N.A., Graban I.V., Ogurtsova T.A. Minocycline (Minolexin®) clinical efficacy and tolerability evaluation in women with bacterial-associated chronic cervicitis. Russian Journal of Woman and Child Health. 2023;6(4):340–346 (in Russ.). DOI: 10.32364/2618-8430-2023-6-4-3.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
